Fulcrum Therapeutics, Inc. (FULC) insider trading

By person

22 insiders · 98 transactions

1.0×

Alex C. Sapir holds only 1.0 times base salary in stock. $680.63K of shares against $650.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Alex C. Sapir last reported holding, valued at $3.52, the price Common Stock was last bought or sold at on the open market here, on 17 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Ra Capital Management, L.p. entity

10% owner

$40.00M (8)

$58.38M (3)

−$18.38M

6,053,960

$21.31M

−57.1%

Robert J Gould

Director

—

$4.94M (29) scheduled

−$4.94M

454,864

$1.60M

−18.4%

Casdin Capital, LLC entity

10% owner

$2.22M (3)

—

+$2.22M

604,285

$2.13M

—

6 Dimensions Capital, L.P. entity

10% owner

$1.90M (1)

—

+$1.90M

559,821

$1.97M

—

Sanofi

10% owner

$1.50M (1)

—

+$1.50M

558,035

$1.96M

—

Kevin Tang

10% owner

$1.49M (6)

—

+$1.49M

7,080,945

$24.92M

+6.3%

Mark J Levin

Director

$1.30M (1)

—

+$1.30M

9,924,404

$34.93M

+58.8%

Third Rock Ventures III, L.P. entity

10% owner

$1.30M (1)

—

+$1.30M

1,962,202

$6.91M

+586.8%

Third Rock Ventures IV, L.P. entity

10% owner

$1.30M (1)

—

+$1.30M

2,343,154

$8.25M

—

Bryan Stuart

See Remarks

—

$1.23M (2) scheduled

−$1.23M

$0.00

—

Christopher Moxham

Chief Scientific Officer

—

$911.42K (2) scheduled

−$911.42K

31,071

$109.37K

0.0%

Alex Sapir

See Remarks

$492.03K (1)

—

+$492.03K

193,360

$680.63K

—

Peter G. Thomson

VP Finance & Accounting

$20.70K (1)

$456.33K (8)

−$435.63K

17,512

$61.64K

−55.5%

Owen B. Wallace

Chief Scientific Officer

—

$245.44K (6) scheduled

−$245.44K

133,438

$469.70K

+5.0%

Diego Cadavid

SVP Clinical Development

—

$205.75K (13) scheduled

−$205.75K

65,714

$231.31K

−7.5%

James A Geraghty

Director

$91.60K (1)

—

+$91.60K

90,714

$319.31K

+12.4%

Alan Ezekowitz

Director

—

$65.61K (1)

−$65.61K

10,927

$38.46K

−62.2%

Greg Tourangeau

Principal Accounting Officer

—

$62.26K (4)

−$62.26K

14,062

$49.50K

−15.5%

Curtis Gale Oltmans

Chief Legal Officer

$9.80K (1)

$44.60K (1)

−$34.80K

10,252

$36.09K

−18.7%

Christopher Morabito

Chief Medical Officer

$10.08K (1)

—

+$10.08K

1,100

$3.87K

—

GSK plc entity

10% owner

—

1,785,714

$6.29M

—

Section 32 Fund 2, LP entity

10% owner

—

464,285

$1.63M

—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Fulcrum Therapeutics, Inc.

What the insiders did Net selling

By person